S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:BIIB

Biogen (BIIB) Stock Forecast, Price & News

$296.41
-2.28 (-0.76%)
(As of 05/31/2023 ET)
Compare
Today's Range
$294.81
$299.58
50-Day Range
$265.17
$318.06
52-Week Range
$188.54
$319.74
Volume
1.57 million shs
Average Volume
973,762 shs
Market Capitalization
$42.90 billion
P/E Ratio
13.76
Dividend Yield
N/A
Price Target
$328.38

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
10.8% Upside
$328.38 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.43mentions of Biogen in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$982,911 Sold Last Quarter
Proj. Earnings Growth
5.78%
From $15.40 to $16.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

417th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

56th out of 167 stocks


BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (BIIB)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Analyst Ratings for Biogen
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Short Interest in Biogen Inc. (NASDAQ:BIIB) Grows By 13.5%
Biogen (BIIB) Receives a Hold from Bank of America Securities
3 Reasons to Buy Biogen Stock (and 1 to Sell)
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
4/25/2023
Today
6/01/2023
Next Earnings (Estimated)
7/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$328.38
High Stock Price Forecast
$371.00
Low Stock Price Forecast
$263.00
Forecasted Upside/Downside
+10.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
26 Analysts

Profitability

Net Income
$3.05 billion
Pretax Margin
36.45%

Debt

Sales & Book Value

Annual Sales
$10.17 billion
Cash Flow
$21.36 per share
Book Value
$95.25 per share

Miscellaneous

Free Float
143,801,000
Market Cap
$42.90 billion
Optionable
Optionable
Beta
0.19

Social Links


Key Executives

  • Christopher A. Viehbacher
    President, Chief Executive Officer & Director
  • Nicole Murphy
    Head-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Executive VP, Head-Research & Development













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

26 analysts have issued 1 year price targets for Biogen's stock. Their BIIB share price forecasts range from $263.00 to $371.00. On average, they anticipate the company's share price to reach $328.38 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the start of the year. Since then, BIIB stock has increased by 7.0% and is now trading at $296.41.
View the best growth stocks for 2023 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 30.4% from the April 30th total of 2,270,000 shares. Based on an average daily volume of 905,900 shares, the short-interest ratio is currently 3.3 days. Approximately 2.1% of the company's stock are short sold.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its quarterly earnings results on Tuesday, April, 25th. The biotechnology company reported $3.40 earnings per share for the quarter, beating analysts' consensus estimates of $3.25 by $0.15. The biotechnology company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.34 billion. Biogen had a net margin of 30.99% and a trailing twelve-month return on equity of 19.60%. The business's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.62 EPS.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $15.00-$16.00 for the period, compared to the consensus earnings per share estimate of $15.48. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.66%), State Street Corp (4.67%), Wellington Management Group LLP (3.77%), Geode Capital Management LLC (2.14%), Envestnet Asset Management Inc. (1.77%) and Price T Rowe Associates Inc. MD (1.44%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $296.41.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $42.90 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $21.54 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -